These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1587296)

  • 1. CA 125 in monitoring clinical course in ovarian cancer patients. A prospective clinical study.
    Markowska J; Manys G; Szewierski Z
    Eur J Gynaecol Oncol; 1992; 13(2):201-4. PubMed ID: 1587296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of CA 125 as a marker of ovarian cancer.
    Markowska J; Manys G; Kubaszewska M
    Eur J Gynaecol Oncol; 1992; 13(4):360-5. PubMed ID: 1516589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors.
    Vinokurov VL; Dudarev AL; Jurkova LE; Lapchenkov VI; Barbanel EJ
    Eur J Gynaecol Oncol; 1992; 13(2):205-8. PubMed ID: 1587297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma.
    Högberg T; Kågedal B
    Acta Obstet Gynecol Scand; 1990; 69(5):423-9. PubMed ID: 2270768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas.
    Molina R; Ojeda B; Filella X; Borras G; Jo J; Mas E; Lopez JJ; Ballesta A
    Tumour Biol; 1992; 13(5-6):278-86. PubMed ID: 1290025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA 125 in monitoring chemotherapy of the patients with ovarian cancer.
    Markowska J; Kojczynski Z; Szewierski Z; Manys G
    Eur J Gynaecol Oncol; 1990; 11(3):209-14. PubMed ID: 2209640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
    J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
    Meisel M; Straube W; Weise J; Burkhardt B
    Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Annicchiarico C; Prato B; Bianchi R; Fioretti P
    Tumour Biol; 1992; 13(5-6):287-93. PubMed ID: 1290026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
    Meden H; Rath W; Teichmann A; Kuhn W
    Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
    Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
    Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 125 half-life in ovarian cancer: a multivariate survival analysis.
    Yedema CA; Kenemans P; Voorhorst F; Bon G; Schijf C; Beex L; Verstraeten A; Hilgers J; Vermorken J
    Br J Cancer; 1993 Jun; 67(6):1361-7. PubMed ID: 8512822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
    Riedinger JM; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
    Bull Cancer; 1996 Aug; 83(8):654-63. PubMed ID: 8869046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of determination of CA-125 in monitoring patients with ovarian carcinoma.
    Kamińska JA; Kowalska MM; Sablińska B; Pietrzak P
    Eur J Gynaecol Oncol; 1993; 14 Suppl():128-32. PubMed ID: 8200363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic significance of the CA 125 half-life for the further outcome of ovarian cancer].
    Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
    Geburtshilfe Frauenheilkd; 1992 Sep; 52(9):526-32. PubMed ID: 1397953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA-125 monitoring during chemotherapy for ovarian cancer.
    Martoni A; Bellucco A; Marabini A; Orlandi C; Platé L; Bianchi D; Pannuti F
    Int J Biol Markers; 1986; 1(3):121-8. PubMed ID: 3480916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of estimating CA 125 in fluids from benign or malignant cysts, in the exudate and blood serum in women with ovarian cancer.
    Markowska J; Kopczyński Z; Szewierski Z; Markowski M; Niecewicz R
    Eur J Gynaecol Oncol; 1994; 15(1):29-32. PubMed ID: 8206067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of the ovarian cancer-associated antigen CA 125 in monitoring tumor burden and response to chemotherapy.
    Quaranta M; Coviello M; Donadeo A; Rella C; Lorusso V; Micelli G; Lucarelli C
    Tumori; 1991 Apr; 77(2):167-9. PubMed ID: 2048231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of Ca 125 in preoperative diagnosis of adnexa tumors].
    Krämer S; Jäger W; Schönwälder A; Wildt L; Lang N
    Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():48-9. PubMed ID: 8118355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.